Lixte Biotechnology Holdings Inc (LIXT)
2.460
+0.08
(+3.38%)
USD |
NASDAQ |
May 17, 16:00
2.29
-0.17
(-6.93%)
After-Hours: 20:00
Lixte Biotechnology Holdings Cash from Financing (Quarterly): 0.00 for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 3.137M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.0063M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 5.152M |
| March 31, 2022 | -0.0109M |
| December 31, 2021 | 0.01M |
| September 30, 2021 | 0.09M |
| June 30, 2021 | 0.101M |
| March 31, 2021 | 3.696M |
| December 31, 2020 | 4.732M |
| September 30, 2020 | -0.0744M |
| June 30, 2020 | -0.0558M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | |
| December 31, 2018 | 4.475M |
| September 30, 2018 | 0.003M |
| June 30, 2018 | |
| March 31, 2018 |
| Date | Value |
|---|---|
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.018M |
| June 30, 2017 | 1.50M |
| March 31, 2017 | 1.00M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.5813M |
| March 31, 2016 | 1.167M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.315M |
| March 31, 2015 | 1.737M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 1.412M |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 2.468M |
| March 31, 2012 | 0.0333M |
| December 31, 2011 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0744M
Minimum
Sep 2020
5.152M
Maximum
Jun 2022
0.8392M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| iBio Inc | 4.005M |
| PAVmed Inc | 19.05M |
| Moleculin Biotech Inc | 0.00 |
| Syros Pharmaceuticals Inc | -0.265M |
| Nutriband Inc | -0.005M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.7892M |
| Free Cash Flow | -3.811M |
| Free Cash Flow Per Share (Quarterly) | -0.3509 |
| Free Cash Flow Yield | -75.16% |